The recent surge in poison control calls linked to semaglutide, marketed as Ozempic and Wegovy, has sparked a crucial conversation about the potential pitfalls of expanding drug approvals. This issue came to light after an undergraduate research project at UT San Antonio, led by Jordan Miller, analyzed the dramatic increase in poison control cases related to GLP-1RAs, particularly semaglutide.
The Rise of Semaglutide and its Unintended Consequences
Semaglutide, initially approved for type 2 diabetes, gained widespread popularity when the FDA expanded its use for chronic weight management in 2021. However, this expanded approval coincided with a surge in poison control calls, with semaglutide being a prominent culprit. David Han, Miller's mentor, suspected that the increase in calls was due to the misuse and mishandling of the drug, especially after its weight management approval.
Unraveling the Data
Miller, working with Han and other researchers, delved into national poison control data. They found that before 2021, poison control centers handled around 1,000 to 1,500 GLP-1RA-related cases annually. However, after mid-2021, this number nearly doubled, and by 2023, it had skyrocketed to over 8,000 calls. Most of these incidents were due to accidental overdosing or therapeutic mistakes, rather than intentional misuse.
A Clear Turning Point
The research team's analysis revealed a clear turning point: the FDA's approval of semaglutide for weight management. The nature and volume of poison control calls changed significantly after this approval, indicating the drug's expanded use beyond diabetic patients to a broader population seeking weight loss. Han emphasized the need to educate the public about the drug's behavior in the body and its long-term safety, which is still not fully understood.
Preventable Mistakes and Education
Many of the poison control cases could have been avoided with better patient education. Semaglutide is designed for weekly injections, not daily, and the dosage is meant to be increased gradually over time. However, common mistakes included taking the medication daily and starting with the highest dose immediately. Improving education at every stage of the prescribing process could significantly reduce these medication errors.
The Power of Data Science
This research project, which began with Miller's curiosity and a simple question to a professor, highlights the power of data science in uncovering public health trends. As Han noted, statistics and data science are meant to help people, transforming data into meaningful insights and informed actions. This project demonstrates the impact of these tools in identifying and addressing potential health risks associated with drug approvals.
A Call for Caution and Education
The semaglutide case serves as a reminder of the importance of thorough education and caution when introducing new drug approvals, especially those with a broader reach. While the drug's weight management approval offers a promising solution for many, it also carries potential risks that require careful management and public awareness. This research not only highlights a public health concern but also emphasizes the need for a balanced approach to drug approvals, considering both the benefits and potential pitfalls.
